--- title: "Replimune Group (REPL) news: class action" url: "https://aibio.space/companies/replimune/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "REPL class action news: Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits. Replimune Group, Inc." --- REPL Replimune Group, Inc. NASDAQ · United States # Replimune Group (REPL) news REPL class action news Legal · 2026-10-28 ## [Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits](https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/) The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action. ## Latest Replimune Group news 1. 2026-02-03 Debt Financing [Replimune amends Hercules loan, draws $35 million and delays repayment to October 2027](https://aibio.space/news/replimune-amends-hercules-loan-draws-35-million-delays-repayment/) The Third Amendment raises the third tranche to $35 million, which was funded at closing, and sets the interest rate at the greater of 8.50% or Prime plus 1.75%. Replimune says its cash runway now reaches late into the first quarter of 2027. 2. 2025-03-07 Financings [Replimune adds Baker Bros. employee to board, grants BBA Funds resale registration rights](https://aibio.space/news/replimune-adds-baker-bros-employee-board-grants-bba-funds-resale/) Replimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024. ## Replimune Group at a glance - **Ticker**: REPL - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $307.8 million ### Related companies - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [Agenus](https://aibio.space/companies/agenus/) NASDAQ: AGEN - [NovelStem International](https://aibio.space/companies/novelstem-international/) OTC: NSTM - [Evofem Biosciences](https://aibio.space/companies/evofem-biosciences/) OTC: EVFM - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTC: OTLC - [4D Molecular Therapeutics](https://aibio.space/companies/4d-molecular-therapeutics/) NASDAQ: FDMT - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD ### Also on NASDAQ - [Inovio Pharmaceuticals](https://aibio.space/companies/inovio-pharmaceuticals/) INO - [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR - [Beta Bionics](https://aibio.space/companies/beta-bionics/) BBNX - [NEOGEN CORP](https://aibio.space/companies/neogen/) NEOG - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) RLAY ## Replimune Group annual financials | Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 | |---|---|---| | Research and development | [$221.2 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | [$189.4 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | | Net income (loss) | [-$313.9 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | [-$247.3 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | | Cash from operations | [-$280.3 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | [-$192.2 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | | Cash and equivalents | [$209.0 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/) | [$111.1 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | | Short-term investments | [$59.9 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/) | [$372.7 million](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $307.8 million, plus short-term investments of $0, $307.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Replimune Group Is there a class action against Replimune Group? Our latest story on this, dated Oct 28, 2026: "Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/). What is the ticker symbol of Replimune Group? Replimune Group, Inc. trades under the ticker REPL on NASDAQ. Where is Replimune Group listed? Replimune Group, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:7R8; LS:A2JQN1. What is the SEC CIK of Replimune Group? The SEC Central Index Key (CIK) for Replimune Group, Inc. is 1737953. Its filings are on SEC EDGAR. How many shares does Replimune Group have outstanding? 94,219,634 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Replimune Group listed under? Our directory records Replimune Group, Inc. under United States. What does Replimune Group do? Our directory classifies Replimune Group, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Replimune Group? The ISIN recorded for Replimune Group, Inc. is US76029N1063. Does aibio.space cover Replimune Group? aibio.space lists Replimune Group, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Replimune Group incorporated? SEC records list its state or country of incorporation as DE. Is Replimune Group profitable? Replimune Group, Inc. reported a net loss of $313.9 million for the fiscal year ended Mar 31, 2026, and used $280.3 million of cash in operations, per its annual report to the SEC. How much does Replimune Group spend on research and development? $221.2 million in the fiscal year ended Mar 31, 2026, per its annual report. How much cash does Replimune Group have? $307.8 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. What is the latest Replimune Group (REPL) stock news? Our latest story on Replimune Group, dated Oct 28, 2026: "Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits". The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action. [Source](https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/). What is Replimune Group's latest stock offering or financing news? Our latest financing story, dated Mar 7, 2025: "Replimune adds Baker Bros. employee to board, grants BBA Funds resale registration rights". Replimune's board grew from nine to ten members on March 5, 2025 to seat Michael Goller, an employee of Baker Bros. Advisors. The same day the company agreed to resale registration rights for the BBA Funds, which bought stock in two financings in 2024. [Source](https://aibio.space/news/replimune-adds-baker-bros-employee-board-grants-bba-funds-resale/). ## Investor discussion: Replimune Group Members talk about Replimune Group (REPL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Replimune Group, newest first. Each line links the filing it comes from. 1. 2026-09-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1737953/000110465926108243/tm2625488d1_8k.htm) 2. 2026-08-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm) 3. 2026-06-29 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm) 4. 2025-08-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1737953/000173795325000013/repl-20250630.htm) 5. 2025-03-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1737953/000110465925021756/tm258605d1_8k.htm) 6. 2024-11-25 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1737953/000110465924122298/tm2429370-2_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:REPL on TradingView](https://www.tradingview.com/symbols/NASDAQ-REPL/). ## SEC filings and registration - **SEC name**: Replimune Group, Inc. - **CIK**: 1737953 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: REPL (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: March 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 500 UNICORN PARK, WOBURN, MA, 01801 - **Phone**: (781) 222-9600 - **Shares outstanding**: 94,219,634 as of 2026-08-11 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926108243/tm2625488d1_8k.htm) filed 2026-09-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1737953/000162828026057099/repl-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_8k.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093042/tm2622673d1_8k.htm) filed 2026-08-10 - [424B5](https://www.sec.gov/Archives/edgar/data/1737953/000110465926093040/tm2622669-1_424b5.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926092246/tm2622487d1_8k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/tm2621708d1_8k.htm) filed 2026-07-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465926088481/tm2621663d1_8k.htm) filed 2026-07-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001737953), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Replimune Group, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker REPL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Replimune Group, Inc. - **Ticker**: REPL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US76029N1063 - **Other listed symbols**: GETTEX:7R8; LS:A2JQN1 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-REPL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/replimune/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Replimune Group (REPL) news: class action", 2026-10-31, https://aibio.space/companies/replimune/